ARCTURUS THERAPEUTICS HOLDINGS INC. (ARCT) EBITDA
- 2026-06-30: Basis Reported; EBITDA (m); Operating income -$25.55M; Depreciation and amortization (m).
- 2026-03-31: Basis Reported; EBITDA (m); Operating income -$28.93M; Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA (m); Operating income -$16.51M; Depreciation and amortization (m).
- 2025-06-30: Basis Reported; EBITDA (m); Operating income -$11.62M; Depreciation and amortization (m).
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | Reported | (m) | -$25.55M | (m) | $2.96M | (m) | $0.00* | -$19.91M* | (m) | $17.52M | (m) | $0.00 |
| 2026-03-31 | Reported | (m) | -$28.93M | (m) | $2.06M | (m) | $0.00 | -$19.44M | (m) | $21.53M | (m) | (m) |
| 2025-09-30 | Reported | (m) | -$16.51M | (m) | $17.15M | (m) | $181.00K* | -$17.15M* | (m) | $23.27M | (m) | $0.00* |
| 2025-06-30 | Reported | (m) | -$11.62M | (m) | $28.30M | (m) | $0.00* | -$5.75M* | (m) | $29.58M | (m) | $4.00K |
| 2025-03-31 | Reported | (m) | -$16.83M | (m) | $29.38M | (m) | $137.00K | -$35.14M | (m) | $34.89M | (m) | $0.00 |
| 2024-09-30 | Reported | (m) | -$10.74M | (m) | $41.67M | (m) | $80.00K* | -$23.76M* | (m) | $39.13M | (m) | -$217.00K |
| 2024-06-30 | Reported | (m) | -$21.13M | (m) | $49.86M | (m) | $328.00K* | -$30.14M* | (m) | $58.67M | (m) | -$150.00K |
| 2024-03-31 | Reported | (m) | -$30.41M | (m) | $38.01M | (m) | $240.00K | -$5.56M | (m) | $53.57M | (m) | $368.00K |
| 2023-09-30 | Reported | (m) | -$19.31M | (m) | $45.14M | (m) | $981.00K* | -$32.41M* | (m) | $51.08M | (m) | $893.00K |
| 2023-06-30 | Reported | (m) | -$55.37M | (m) | $10.52M | (m) | $354.00K* | $50.81M* | (m) | $52.67M | (m) | $577.00K |
| 2023-03-31 | Reported | (m) | $14.76M | (m) | $80.28M | (m) | $691.00K | -$35.87M | (m) | $51.77M | (m) | $103.00K |
| 2022-09-30 | Reported | (m) | -$36.81M | (m) | $13.37M | (m) | $2.19M* | -$42.41M* | (m) | $37.69M | (m) | $0.00 |
| 2022-06-30 | Reported | (m) | -$22.09M | (m) | $27.09M | (m) | -$378.00K* | -$36.82M* | (m) | $38.19M | (m) | $0.00 |
| 2022-03-31 | Reported | (m) | -$50.38M | (m) | $5.24M | (m) | $2.11M | -$49.04M | (m) | $44.89M | (m) | $100.00K |
| 2021-12-31 | Reported | (m) | -$37.65M | (m) | $5.79M | (m) | (m) | (m) | (m) | $32.63M | (m) | (m) |
| 2021-09-30 | Reported | (m) | -$53.82M | (m) | $2.44M | (m) | $1.77M* | -$16.65M* | (m) | $45.40M | (m) | $0.00 |
| 2021-06-30 | Reported | (m) | -$53.72M | (m) | $2.00M | (m) | $404.00K* | -$32.94M* | (m) | $45.68M | (m) | $0.00 |
| 2021-03-31 | Reported | (m) | -$57.67M | (m) | $2.13M | (m) | $118.00K | -$42.95M | (m) | $50.05M | (m) | $0.00 |
| 2020-12-31 | Reported | (m) | -$31.08M | (m) | $2.24M | (m) | (m) | (m) | (m) | $24.29M | (m) | (m) |
| 2020-09-30 | Reported | (m) | -$20.94M | (m) | $2.33M | (m) | $434.00K* | -$15.88M* | (m) | $17.70M | (m) | $0.00 |
| 2020-06-30 | Reported | (m) | -$10.04M | (m) | $2.32M | (m) | $469.00K* | -$8.49M* | (m) | $7.94M | (m) | $0.00 |
| 2020-03-31 | Reported | (m) | -$9.46M | (m) | $2.65M | (m) | $142.00K | -$11.86M | (m) | $7.92M | (m) | $0.00 |
| 2019-12-31 | Reported | (m) | -$10.82M | (m) | $2.97M | (m) | (m) | (m) | (m) | $11.99M | (m) | (m) |
| 2019-09-30 | Reported | (m) | -$7.62M | (m) | $3.32M | (m) | $159.00K* | -$2.84M* | (m) | $7.05M | (m) | (m) |
| 2019-06-30 | Reported | (m) | -$572.00K | (m) | $10.15M | (m) | $266.00K* | $9.34M* | (m) | $7.27M | (m) | (m) |
| 2019-03-31 | Reported | (m) | -$6.51M | (m) | $4.35M | (m) | $78.00K | -$5.41M | (m) | $7.32M | (m) | (m) |
| 2018-09-30 | Reported | (m) | -$4.36M | (m) | $3.42M | (m) | $253.00K* | -$6.79M* | (m) | $3.97M | (m) | (m) |
| 2018-06-30 | Reported | (m) | -$10.07M | (m) | $2.39M | (m) | (m) | (m) | (m) | $4.22M | (m) | (m) |
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | Reported | (m) | -$76.26M | (m) | $82.03M | (m) | $230.00K | -$74.27M | (m) | $112.21M | (m) | (m) |
| 2024-12-31 | Reported | (m) | -$95.67M | (m) | $152.31M | (m) | $648.00K | -$59.75M | (m) | $195.16M | (m) | -$4.00K |
| 2023-12-31 | Reported | (m) | -$78.20M | (m) | $166.80M | (m) | $2.90M | -$18.10M | (m) | $192.13M | (m) | $1.83M |
| 2022-12-31 | Reported | (m) | $12.18M | (m) | $206.00M | (m) | $7.73M | $31.99M | (m) | $147.75M | (m) | $1.29M |
| 2022-09-30 | Rolling | (m) | -$146.92M* | (m) | $51.50M* | (m) | (m) | (m) | (m) | $153.40M* | (m) | (m) |
| 2022-06-30 | Rolling | (m) | -$163.93M* | (m) | $40.57M* | (m) | (m) | (m) | (m) | $161.11M* | (m) | (m) |
| 2022-03-31 | Rolling | (m) | -$195.56M* | (m) | $15.48M* | (m) | (m) | (m) | (m) | $168.60M* | (m) | (m) |
| 2021-12-31 | Reported | (m) | -$202.85M | (m) | $12.36M | (m) | $3.41M | -$135.04M | (m) | $173.76M | (m) | (m) |
| 2021-12-31 | Rolling | (m) | -$202.85M* | (m) | $12.36M* | (m) | (m) | (m) | (m) | $173.76M* | (m) | (m) |
| 2021-09-30 | Rolling | (m) | -$196.29M* | (m) | $8.80M* | (m) | (m) | (m) | (m) | $165.41M* | (m) | (m) |
| 2021-06-30 | Rolling | (m) | -$163.41M* | (m) | $8.70M* | (m) | (m) | (m) | (m) | $137.71M* | (m) | (m) |
| 2021-03-31 | Rolling | (m) | -$119.73M* | (m) | $9.02M* | (m) | (m) | (m) | (m) | $99.98M* | (m) | (m) |
| 2020-12-31 | Reported | (m) | -$71.52M | (m) | $9.54M | (m) | $1.74M | -$42.86M | (m) | $57.85M | (m) | (m) |
| 2020-12-31 | Rolling | (m) | -$71.52M* | (m) | $9.54M* | (m) | (m) | (m) | (m) | $57.85M* | (m) | (m) |
| 2020-09-30 | Rolling | (m) | -$51.26M* | (m) | $10.27M* | (m) | (m) | (m) | (m) | $45.55M* | (m) | (m) |
| 2020-06-30 | Rolling | (m) | -$37.94M* | (m) | $11.25M* | (m) | (m) | (m) | (m) | $34.91M* | (m) | (m) |
| 2020-03-31 | Rolling | (m) | -$28.47M* | (m) | $19.09M* | (m) | (m) | (m) | (m) | $34.23M* | (m) | (m) |
| 2019-12-31 | Reported | (m) | -$25.51M | (m) | $20.79M | (m) | $818.00K | -$6.45M | (m) | $33.64M | (m) | (m) |
| 2019-12-31 | Rolling | (m) | -$25.51M* | (m) | $20.79M* | (m) | (m) | (m) | (m) | $33.64M* | (m) | (m) |
| 2018-12-31 | Reported | (m) | -$21.81M | (m) | $15.75M | (m) | $1.48M | -$20.76M | (m) | $16.98M | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |